ABP 414
Phase 3
AmgenABP 414 is one of 51 therapeutic programs targeting Breast Carcinoma. It is currently in Phase 3.
1
Indications
0
Total Trials
0
Active Trials
50
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
88 competitors in Breast Carcinoma
#DrugCompanyPhaseTrials
1Tykerb
NovartisApproved
Piqray
NovartisApproved
Gemzar
Johnson & JohnsonApproved
Tagrisso
AstraZenecaApproved
Bayer Aspirin
BayerApproved
Faslodex
FFresenius Kabi Oncology Ltd.
Approved
Bosulif
PPrism Pharmaceuticals
Approved
Taxol
TevaPhase 3
Tecentriq
RochePhase 3
Imfinzi
AstraZenecaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for ABP 414. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3
- Company